denileukin diftitox-cxdl 300 MCG Injection

RxCUI: 2700750
RxNorm name: denileukin diftitox-cxdl 300 MCG Injection
Display name: denileukin diftitox-cxdl 300 MCG Injection
Full name: denileukin diftitox-cxdl 300 MCG Injection
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:15

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761312	Lymphir	denileukin diftitox-cxdl	351(a)	Rx	2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
LYMPHIR	DENILEUKIN DIFTITOX-CXDL	Citius Pharmaceuticals, Inc.	ac3613d7-4304-40e7-a3f5-adb8a8adca5d	2025-01-23	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2700750

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
ac3613d7-4304-40e7-a3f5-adb8a8adca5d	denileukin diftitox-cxdl 300 MCG Injection [PSN] · denileukin diftitox-cxdl 0.3 MG Injection [SCD] · denileukin diftitox-cxdl 300 MCG Injection [SY]	3	7	These highlights do not include all the information needed to use LYMPHIR™ safely and effectively. See full prescribing information for LYMPHIR. LYMPHIR™ (denileukin diftitox-cxdl) for injection, for intravenous use Initial U.S. Approval: 2024	20250123